TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

TELA Bio, Inc.NASDAQ: TELA

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $11.26M (cash outflow) rose 13.5% year over year, ahead of the +1.0% change in trailing-twelve-month net income. Sequentially, it fell 8.2% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.

Context

  • Net income amounted to 48.4% of revenue in FY2025, down 6.2 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$31.82M (-18.1%) for the fiscal year ending Dec 2026, a slowdown from the +2.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$11.26M-8.2% QoQ
Last fiscal yearDec 2025
-$38.83M+2.6% YoY
LTMJun 2026
-$41.18M+1.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.5%+3.9%-9.6 pp
1 year+2.6%-18.1%-20.7 pp
3-year CAGR-4.3%-26.0%-21.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(38.83M) USD
Year-over-year change
-2.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 net income of $41.18M is the 2nd largest of the 9 companies compared; the peer median is $19.29M.
  • Its year-over-year change of +1.0% is the 5th highest of 9, against a peer median of -15.6%.
  • Net income amounts to 51.5% of revenue for TELA, versus a peer median of 491.3%.
TELA Competitors Peer median
Net Income for TELA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M -388.6%-1.9%18297.5%
TELATELA Bio, Inc.LTM Jun 2026$41.18M +1.0%-4.3%51.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$37.19M -32.9%-5.5%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$24.54M +1.8%-10.4%1070.2%
CUECue Biopharma, Inc.LTM Mar 2026$19.52M -51.9%-20.5%59.6%
EQEquillium, Inc.LTM Mar 2026$19.06M +36.2%-28.9%—
MDAISpectral AI, Inc.LTM Mar 2026$13.88M +50.7%+37.5%83.1%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$12.72M +12.6%-31.8%899.5%
SRTSSensus Healthcare, Inc.LTM Mar 2026$7.77M -531.6%—34.5%
Peer median (excluding TELA) $19.29M-15.6%-10.4%491.3%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Depreciation & Amortization535K1.19M808K1.01M1.01M
Deferred Income Tax14K00(144K)230K
Stock-Based Compensation3.66M3.99M5.03M4.36M3.8M
Change in Working Capital(3.47M)(5.76M)(1.67M)(4.87M)1.5M
Accounts Receivables(1.55M)(2.42M)(3.06M)(762K)(110K)
Inventory(5.19M)(6.07M)(2.72M)(2.97M)(503K)
Accounts Payables1.6M(884K)11K482K141K
Other Working Capital1.69M3.62M4.1M(1.62M)1.97M
Other Non-Cash Items2.1M4.14M1.64M(4.12M)4.08M
Operating Cash Flow(30.43M)(40.75M)(40.86M)(41.6M)(28.22M)
Capital Expenditures(627K)(1.87M)(611K)(989K)(448K)
Acquisitions (Net)00001.29M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(1M)12K5.44M0
Investing Cash Flow(627K)(1.87M)(599K)4.45M846K
Debt Repayment010M0014.03M
Common Stock Issued585K34.4M46.34M42.92M11.82M
Common Stock Repurchased0000105K
Dividends Paid00000
Other Financing Activities0(3.55M)(74K)138K(205K)
Financing Cash Flow585K40.85M46.27M43.06M25.75M
Effect of Forex Changes11K(144K)164K28K(217K)
Net Change in Cash(30.46M)(1.91M)4.98M5.94M(1.84M)
Free Cash Flow(31.06M)(42.62M)(41.47M)(42.58M)(28.67M)

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.